ABVC BioPharma (ABVC) 10-K 16 Jan 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017	Jan. 11, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	American BriVision (Holding) Corp
Entity Central Index Key	1,173,313
Trading Symbol	MTOO
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Document Type	10-K
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float		$ 69,924,306
Entity Common Stock, Shares Outstanding			213,746,647

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2017	Sep. 30, 2016
Current assets
Cash	$ 204,851	$ 173,537
Receivable from collaboration partners – related parties	2,550,000
Total Current Assets	2,754,851	173,537
Deposit		3,815
Total Assets	2,754,851	177,352
Liabilities and Equity
Accounts payable		18,370
Accrued expense	34,914	38,100
Due to related parties	4,113,000	6,500,000
Total Liabilities	4,147,914	6,556,470
Commitments and Contingencies
Stockholders’ deficit
Common Stock 360,000,000 authorized at $0.001 par value; shares issued and outstanding 213,746,647 and 210,821,647 at September 30, 2017 and September 30, 2016, respectively	213,747	210,822
Additional paid-in capital	13,788,574	4,733,461
Accumulated deficit	(15,395,384)	(11,323,401)
Total stockholders’ deficit	(1,393,063)	(6,379,118)
Total Liabilities and Equity	$ 2,754,851	$ 177,352

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Sep. 30, 2016
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	360,000,000	360,000,000
Common stock, shares issued	213,746,647	210,821,647
Common stock, shares outstanding	213,746,647	210,821,647

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Revenues
Cost of revenues		32
Gross profit (loss)		(32)
Operating expenses
Selling, general and administrative expenses	707,142	599,303
Research and development expenses	3,151,162	10,000,000
Stock based compensation expenses	138,038	397,960
Loss from operations	(3,996,342)	(10,997,295)
Other income(expenses)
Interest income	149	361
Gain on exchange differences		141
Interest expense	(74,960)	(10,170)
Total other expenses	(74,811)	(9,668)
Loss from continuing operations before provision income tax	(4,071,153)	(11,006,963)
Provision income tax	830	836
Net Loss	$ (4,071,983)	$ (11,007,799)
Net loss per share
Basic and diluted	$ (0.02)	$ (0.06)
Weighted average number of common shares outstanding
Basic and diluted	212,648,770	193,981,153

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($)	Common Stock [Member]	Additional paid-in capital	Subscription receivable	Retained Earnings [Member]	Total
Balance at Jul. 20, 2015	$ 159,623	$ 1,087,378	$ (350,000)		$ 897,001
Balance, shares at Jul. 20, 2015	159,622,964
Issuance of common shares	$ 6,651	45,307			51,958
Issuance of common shares, shares	6,650,957
Net loss for the period				(315,602)	(315,602)
Balance at Sep. 30, 2015	$ 166,274	1,132,685	(350,000)	(315,602)	633,357
Balance, shares at Sep. 30, 2015	166,273,921
Issuance of common shares	$ 2,032	3,247,968			3,250,000
Issuance of common shares, shares	2,031,423
Reverse merger recapitalization	$ 42,359	(44,995)			(2,636)
Reverse merger recapitalization, shares	42,359,253
Stock based compensation	$ 157	397,803			397,960
Stock based compensation, shares	157,050
Receipt of subscription receivable			350,000		350,000
Net loss for the period				(11,007,799)	(11,007,799)
Balance at Sep. 30, 2016	$ 210,822	4,733,461		(11,323,401)	(6,379,118)
Balance, shares at Sep. 30, 2016	210,821,647
Issuance of common shares	$ 2,925	5,847,075			5,850,000
Issuance of common shares, shares	2,925,000
Stock based compensation		138,038			138,038
Capital contribution from related parties under common control		3,070,000			3,070,000
Net loss for the period				(4,071,983)	(4,071,983)
Balance at Sep. 30, 2017	$ 213,747	$ 13,788,574		$ (15,395,384)	$ (1,393,063)
Balance, shares at Sep. 30, 2017	213,746,647

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities
Net loss from continuing operations	$ (4,071,983)	$ (11,007,799)
Adjustments to reconcile net loss to net cash used by operating activities:
Issuance of common stock for compensation and recapitalization		1,295,324
Stock based compensation for nonemployees	138,038
Change in operating assets and liabilities:
Decrease in prepaid expenses and deposits	3,815	3,815
Increase (decrease) in accounts payable	(18,370)	18,370
Decrease in accrued expenses and other current liabilities	(3,186)	(261,900)
Increase in due to related parties	2,353,000	6,477,483
Net cash used in operating activities	(1,598,686)	(3,474,707)
Cash flows from financing activities
Capital contribution from related parties under common control	520,000
Borrowings from related parties	1,110,000
Decrease in due to shareholders		(46,586)
Proceeds from subscription receivable		350,000
Proceeds from issuance of common shares		2,350,000
Net cash provided by financing activities	1,630,000	2,653,414
Effect of exchange rates on cash
Net increase (decrease) in cash	31,314	(821,293)
Cash, beginning of period	173,537	994,830
Cash, end of period	204,851	173,537
Supplemental disclosure of cash flow information
Interest expense paid	66,500
Income taxes paid	830	836
Non-cash financing and investing activities
Common shares issued for due to related parties	5,850,000
Capital contribution from related parties under common control	$ 2,550,000

Organization and Description of

Organization and Description of Business	12 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	1. ORGANIZATION AND DESCRIPTION OF BUSINESS American BriVision (Holding) Corporation (the “Company” or “Holding entity”), a Nevada corporation, through the Company’s operating entity, American BriVision Corporation (the “BriVision”), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (“MSKCC”) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets. BriVision had to predecessor operations prior to its formation on July 21, 2015. Reverse Merger On February 8, 2016, a Share Exchange Agreement (the “Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation, American BriVision Corporation (“BriVision”), and Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People’s Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the ”BriVision Stock”). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the ”Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the “Merger”). Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) common shares of the Company and BriVision has become a wholly owned subsidiary of the Company. The holders of Company’s common stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company’s common stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the ”Share Exchange”), BriVision has become a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement. Because of the consummation of the Share Exchange, BriVision is now our wholly owned subsidiary and its shareholders own approximately 79.70% of our issued and outstanding common stock. Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing BriVision’s historically proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets. Accounting Treatment of the Reverse Merger For financial reporting purposes, the Share Exchange represents a “reverse merger” rather than a business combination and BriVision is deemed the accounting acquirer in the transaction. The Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision is the acquirer for financial reporting purposes and the Company is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of BriVision and recorded at the historical cost basis of BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of BriVision and operations of the Combined Company from the closing date of the Share Exchange.

Corrections to Previously Issue

Corrections to Previously Issued Consolidated Financial Statements	12 Months Ended
	Sep. 30, 2017
Accounting Changes and Error Corrections [Abstract]
CORRECTIONS TO PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS	2. CORRECTIONS TO PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS The Company discovered that it had erroneously stated that the research and development expenses were understated during the year ended September 30, 2016. Instead, our research and development expenses were $10,000,000 for the year ended September 30, 2016 and were restated in the Adjustments No. 1 column. Moreover, there were typographical errors on Selling, General and Administration expenses which were corrected in the Adjustments No. 2 column. The following tables present the effect of the corrections discussed above and other adjustments on selected line items of our previously reported consolidated financial statements as of and for the year ended September 30, 2016, ITEMS Previously Reported on Form 10K Adjustments No.1 Adjustments No.2 Restated Consolidated Balance Sheets As of September 30, 2016 Due to related party - 6,500,000 - 6,500,000 Total Liabilities 56,470 6,500,000 - 6,556,470 Additional paid-in capital 4,733,401 - 60 4,733,461 Accumulated deficit (4,823,401 ) (6,500,000 ) - (11,323,401 ) Total equity (deficit) 120,882 (6,500,000 ) - (6,379,118 ) Consolidated Statements of Operations and Comprehensive Loss For the year ended September 30, 2016 Selling, general and administrative expenses 4,497,263 (3,500,060 ) 60 997,263 Research and development expenses - 10,000,000 - 10,000,000 Net loss from operations (4,497,295 ) (6,499,940 ) (60 ) (10,997,295 ) Loss from continuing operations before income taxes (4,506,963 ) (6,499,940 ) (60 ) (11,006,963 ) Net Loss (4,507,799 ) (6,499,940 ) (60 ) (11,007,799 ) Basic and diluted loss per share (0.00 ) (0.06 ) (0.00 ) (0.06 ) Consolidated Statements of Cash Flow For the year ended September 30, 2016 Net loss from continuing operations (4,507,799 ) (6,499,940 ) (60 ) (11,007,799 ) Issuance of common stock for compensation 1,295,324 (60 ) 60 1,295,324 (Decrease) increase in due to related party (22,517 ) 6,500,000 6,477,483 As a result of the restatement of the consolidated balance sheet as of September 30, 2016, Due to related party and Total liabilities were increased by $6,500,000; changed from $0 to $6,500,000 and from $56,470 to $6,556,470. Additional paid in capital was increased by $60 and changed from $4,733,401 to $4,733,461. Accumulated deficit was increased by $6,500,000 and changed from $(4,823,401) to $(11,323,401). Total equity (deficit) was decreased by $6,500,000 and changed from $120,882 to $(6,379,118). As a result of the restatement of the consolidated statement of operations and comprehensive loss for the year ended September 30, 2016, Selling, general and administrative expenses were decreased by $3,500,000 and changed from $4,497,263 to $997,263. Research and development expenses were increased by $10,000,000 and changed from $0 to $10,000,000. Net loss from operations was increased by $6,500,000 and changed from $(4,497,295) to $(10,997,295). Loss from continuing operations before taxes was increased by $6,500,000 and changed from $(4,506,963) to $(11,006,963). Net loss was increased by $6,500,000 and changed from $(4,507,799) to $(11,007,799). Basic and diluted loss per share were also increased by 0.06 and changed from $0 to $(0.06). As a result of the restatement of the consolidated statement of cash flow for the year ended September 30, 2016, Net loss from continuing operations was increased by $6,500,000; changed from $(4,507,799) to $(11,007,799). Issuance of common stock for compensation did not have changes and stated as $1,295,324. (Decrease) increase in due to related party was increased by $6,500,000 and changed from $(22,517) to $6,477,483. There were no changes in Net cash used in operating activities.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the “U.S. GAAP”). All significant intercompany transactions and account balances have been eliminated. This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results. Reclassifications Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit. Forward Stock split On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation. Fair Value Measurements The Company applies the provisions of ASC Subtopic 820-10, ”Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. - Level 3 inputs to the valuation methodology are unobservable and significant to the fair value. There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of September 30, 2017 and 2016. Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2017 and 2016, the Company’s cash and cash equivalents amounted $204,851 and $173,537, respectively. All of the Company’s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality. Concentration of Credit Risk The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes. Concentration of credit risk with respect to trade and notes receivables is limited due to the wide variety of customers and markets in which the Company transacts business, as well as their dispersion across many geographical areas. The Company performs ongoing credit evaluations of its customers and generally does not require collateral, but does require advance deposits on certain transactions. Receivable from Collaboration Partners Receivable from collaboration partners is stated at carrying value less estimates made for doubtful receivables. An allowance for impairment of receivable from collaboration partners is established if the collection of a receivable becomes doubtful. Such receivable becomes doubtful when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the receivable is impaired. The amount of the allowance is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. An impairment loss is recognized in the statement of operations, as are subsequent recoveries of previous impairments. Research and Development Expenses The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred. Stock-based Compensation The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 “Compensation-Stock Compensation”. Total employee stock-based compensation expenses were $0 and $397,960 for the years ended September 30, 2017 and 2016, respectively. The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 505-50 “Equity-Based Payments to Non-Employees” which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $138,038 and $0 for the years ended September 30, 2017 and 2016, respectively. Income Taxes The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain. Under ASC 740, a tax position is recognized as a benefit only if it is ”more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the years ended September 30, 2017 and September, 30, 2016. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition. For the years ended September 30, 2017 and 2016, the Company’s income tax expense amounted $830 and $836, respectively. Loss Per Share of Common Stock The Company reports loss per share in accordance with ASC Topic 260-10 “Earnings per Share.” Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Commitments and Contingencies The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred. Recent Accounting Pronouncements Revenue Recognition: Revenue from Contracts with Customers: Topic Disclosure of Going Concern Uncertainties: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Leases Stock-based Compensation Financial Instruments - Credit Losses: Statement of Cash Flows: In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): “Restricted Cash”(“ASU 2016-18”). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016-18 will become effective for us beginning April 1, 2018, or fiscal 2019. ASU 2016-18 is required to be applied retrospectively. Upon the adoption, amounts described as restricted cash will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts shown on the statements of cash flows. Business Combination From time to time, new accounting pronouncements are issued by FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption. Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying financial statements

Going Concern

Going Concern	12 Months Ended
	Sep. 30, 2017
Going Concern [Abstract]
GOING CONCERN	4. GOING CONCERN The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since its inception resulting in an accumulated deficit of $15,395,384 and $11,323,401 as of September 30, 2017 and 2016, respectively and incurred net loss of $4,086,983 and $11,007,799 during the years ended September 30, 2017 and 2016, respectively. The Company also had a working capital deficiency of $1,393,063 and $6,382,933 at September 30, 2017 and 2016, respectively. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company upon signing of that agreement. On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through enter into the Milestone Payment Agreement, whereby the Company has agreed to pay the Milestone Payment to BioLite $2,600,000 in cash and $900,000 in newly issued shares of its common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016. Pursuant to the BioLite Collaborative Agreement, the 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. On February 2017, the Company agreed to pay this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of its common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. The cash payment and shares issuance were completed in February 2017. This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term. In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management’s plans to obtain such resources for the Company include (1) obtaining capital from the sale of its equity securities (2) short-term and long-term borrowings from banks and third-parties, and (3) short-term borrowings from stockholders or other related party(ies) when needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually to secure other sources of financing and attain profitable operations.

Collaborative Agreements

Collaborative Agreements	12 Months Ended
	Sep. 30, 2017
Collaborative Agreements
COLLABORATIVE AGREEMENTS	5. COLLABORATIVE AGREEMENTS Collaborative agreement with BioLite Inc., a related party On December 29, 2015, American BriVision Corporation entered into a collaborative agreement (the “BioLite Collaborative Agreement”) with BioLite Inc. (the “BioLite”), a related party (See Note 7), pursuant to which BioLite granted BriVision sole licensing rights for drug and therapeutic use of five products, including BLI-1005 CNS-Major Depressive Disorder, BLI-1008 CNS-Attention Deficit Hyperactivity Disorder, BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1, BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer, and BLI-1501 Hematology-Chronic Lymphocytic Leukemia, in the U.S.A and Canada. Under the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of BriVision with equivalent value, according to the following schedule: ● upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week. ● upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week. ● at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months. ● upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week. ● at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months. ● upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week. This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term. Pursuant to the BioLite Collaborative Agreement, an upfront payment of $3,500,000 (the “Milestone Payment”), which is 3.5% of total payments due under the BioLite Collaborative Agreement, was to be paid by the Company upon signing of that agreement. On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company agreed to pay the Milestone Payment to BioLite with $2,600,000 in cash and $900,000 in the form of newly issued shares of its common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016. Pursuant to the BioLite Collaborative Agreement, the 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. On February 2017, the Company agreed to pay this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of its common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. The cash payment and shares issuance were completed in February 2017. Pursuant to the BioLite Collaborative Agreement, the 15% of total payment, $15,000,000 shall be made at the completion of first phase II clinical trial. As of September 30, 2017, the first phase II clinical trial research has not completed yet. The Company determined to fully expense the entire amount of $10,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount is fully expensed as research and development expense. On January 12, 2017, the Company entered into an Addendum (the “Addendum”) to the BioLite Collaborative Agreement which was previously entered into with BioLite. Pursuant to the Addendum, the Company and BioLite agreed to include one more product, namely, “Maitake Combination Therapy” as one of the Products defined in the BioLite Collaborative Agreement (the “Sixth Product’) and defined the Territory of the Sixth Product to be worldwide and restate the Territory of the Five Products to be the U.S.A and Canada. Co-Development agreement with Rgene Corporation, a related party On May 26, 2017, American BriVision Corporation entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation (the “Rgene”), a related party under common control by controlling beneficiary shareholder of Yuangene Corporation and the Company (See Note 7). Pursuant to Co-Dev Agreement, BriVison and Rgene agreed to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum. Under the terms of the Co-Dev Agreement, Rgene should pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision’s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. Besides of $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development cost shall be equally shared by both BriVision and Rgene. On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. As of the date of this report, the Company has received $450,000 in cash. The Company is still in discussion with Rgene with respect to the schedule of the outstanding balance. Collaborative agreement with BioFirst Corporation, a related party On July 24, 2017, American BriVision Corporation entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst Corporation (“BioFirst”), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the “Product”): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of Yuangene Corporation and the Company is one of the directors and common stock shareholders of BioFirst (See Note 7). Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst’s past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst. As of September 30, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. No payment has been made by the Company as of the date of this report. The Company determined to fully expense the entire amount of $3,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended September 30, 2017.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Sep. 30, 2017
Payables and Accruals [Abstract]
ACCRUED EXPENSES	6. ACCRUED EXPENSES Accrued expenses as of September 30, 2017 and 2016 consisted of: September 30, September 30, Accrued consulting fee $ 2,609 $ 23,100 Accrued audit fee - 15,000 Accrued interest expense – related party(Note 7) 8,460 - Accrued payroll 23,845 - Total $ 34,914 $ 38,100

Related Parties Transactions

Related Parties Transactions	12 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
RELATED PARTIES TRANSACTIONS	7. RELATED PARTIES TRANSACTIONS The related parties of the company with whom transactions are reported in these financial statements are as follows: Name of entity or Individual Relationship with the Company and its subsidiaries BioLite Inc. (the “BioLite”) Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene BioFirst Corporation (the “BioFirst”) Entity controlled by controlling beneficiary shareholder of Yuangene Rgene Corporation (the “Rgene”) Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene Liongene Corporation (the “Liongene”) Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene Yuangene Corporation (the “Yuangene”) Controlling beneficiary shareholder of the Company Asiangene Corporation (the “Asiangene”) Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”) Shareholder of the Company Kimho Consultants Co., Ltd. (the “Kimho”) Shareholder of the Company Due to related parties Amount due to related parties consisted of the following as of the periods indicated: September 30, September 30, 2017 2016 BioLite, Inc. $ - $ 6,500,000 BioFirst Corporation 3,950,000 - Asiangene Corporation 160,000 - Yuangene Corporation 3,000 - Total $ 4,113,000 $ 6,500,000 Related party transactions (1) On December 29, 2015, BriVision and BioLite entered into a collaborative agreement (the “BioLite Collaborative Agreement”) Under the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of BriVision with equivalent value based on the milestone achievement (See Note 5). As of September 30, 2017 and 2016, the amount due to BioLite is $0 and $6,500,000 respectively. (2) On January 26, 2017, the Company and BioFirst entered into a loan agreement for a total commitment (non-secured indebtedness) of $950,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on February 1, 2018. As of September 30, 2017, the outstanding loan balance is $950,000 and accrued interest is $8,460 (See Note 6). Interest expenses were $74,960 and $0 for the years ended September 30, 2017 and 2016, respectively. (3) During the year ended September 30, 2017, Yuangene Corporation advanced in an aggregate amount of $3,000 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. As of September 30, 2017, the outstanding advance balance is $3,000. (4) On May 26, 2017, BriVision entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene (See Note 5). As of September 30, 2017, the Company has received an aggregate amount of $450,000 in cash and has recorded $2,550,000 as receivable from collaboration partners. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. (5) On July 24, 2017, BriVision entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst (See Note 5). As of September 30, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded full amount of $3,000,000 due to BioFirst. (6) On January 1, 2017, Euro-Asia Investment & Finance Corp Ltd. and the Company entered into a service agreement (the “Euro-Asia Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the year ended September 30, 2017, the Company recognized non-employee stock based compensation expenses of $55,000 in connection with the terms in the Euro-Asia Agreement. (7) On January 1, 2017, Kimho Consultants Co., Ltd. and the Company entered into a service agreement (the “Kimho Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the year ended September 30, 2017, the Company recognized non-employee stock based compensation expenses of $80,000 in connection with the terms in the Kimho Agreement. (8) During the year ended September 30, 2017, the Company provided a one-time consulting service to Liongene Corporation for $70,000. Since both Liongene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation, the Company has recorded the full amount of $70,000 as additional paid-in capital during the year ended September 30, 2017. (9) During the year ended September 30, 2017, the Company entered an operating lease agreement with Asiangene for an office space in Taiwan for the period from October 1, 2016 to July 31, 2017. The monthly base rent is approximately $5,000. Rent expenses under this lease agreement amounted to $52,205 and $0 for the years ended September 30, 2017 and 2016, respectively. (10) In September 2017, Asiangene entered an investment and equity transfer agreement (the “Investment and Equity Transfer Agreement”) with Everfront Biotech Inc. (the “Everfront”), a third party. Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by Asiangene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. Asiangene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. As of September 30, 2017, the outstanding loan balance is $160,000.

Equity

Equity	12 Months Ended
	Sep. 30, 2017
Equity [Abstract]
EQUITY	8. EQUITY During October 2015, $350,000 of subscription receivable was fully collected from the shareholders. On February 8, 2016, a Share Exchange Agreement (“Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation (the ”Company”), American BriVision Corporation (“BriVision”), Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People’s Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the ”BriVision Stock”). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the ”Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision’s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company’s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company’s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company’s common stock, Because of the exchange of the BriVision Stock for the Acquisition Stock (the ”Share Exchange”), BriVision became a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement. On February17, 2016, pursuant to the 2016 Equity Incentive Plan (the “2016 Plan”), 157,050 (50,000 pre-stock split) shares were granted to the employees. On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the “Forward Stock Split”) and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation. On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of our first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On August 26, 2016, the Company issued 1,468,750 shares (“Shares”) of the Company’s common stock, par value $0.001 (the “Offering”) to BioLite, Inc., a non-U.S. accredited investor (the “Purchaser”) pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the “SPA”). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. The proceeds may be used for general corporate purposes. Pursuant to the BioLite Collaborative Agreement (See Note 5), BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of our common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (“Kameyama”) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s common stock at $1.00 per share for any amount exceeding $3,000. The Company’s stocks shall be calculated and issued in December every year. The contract is terminated on September 30, 2017. The non-employee stock-based compensation related to this consulting agreement was $3,038 for the year ended September 30, 2017. On January 1, 2017, Euro-Asia Investment & Finance Corp Ltd. and the Company entered into a service agreement (the “Euro-Asia Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the year ended September 30, 2017, the Company recognized professional fees of $69,000 and non-employee stock based compensation expenses of $55,000 in connection with the terms in the Euro-Asia Agreement. On January 1, 2017, Kimho Consultants Co., Ltd. and the Company entered into a service agreement (the “Kimho Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the year ended September 30, 2017, the Company recognized professional fees of $113,000 and non-employee stock based compensation expenses of $80,000 in connection with the terms in the Kimho Agreement. Pursuant to ASC 505-50-30, the transactions with the non-employees were measured based on the fair value of the equity instruments issued as the Company determined that the fair value of the equity instruments issued in a stock-based payment transaction with nonemployees was more reliably measurable than the fair value of the consideration received. The Company measured the fair value of the equity instruments in these transactions using the stock price on the date at which the commitments Kameyama, Euro-Asia, and Kimho for performance were rendered.

Income Tax

Income Tax	12 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
INCOME TAX	9. INCOME TAX The Company files income tax returns in the U.S. federal jurisdiction, and various state and local jurisdictions. The Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2013. Components of income tax (benefits) for the years ended September 30, 2017 and 2016 are as follows: For the year ended September 30, 2017 For the year ended September 30, 2016 Federal State Total Federal State Total Current $ - $ 830 $ 830 $ - $ 836 $ 836 Deferred - - - - - - $ - $ 830 $ 830 $ - $ 836 $ 836 Significant components of the Company’s deferred tax accounts at September 30, 2017 and September 30, 2016: Deferred Tax Account - noncurrent: September 30, 2017 September 30, 2016 Tax losses carryforwards $ 832,913 $ 464,038 Less: Valuation allowance (832,913 ) (464,038 ) Total deferred tax account - noncurrent $ - $ - The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below: For the Year ended 2017 2016 Statutory federal tax benefit, net of state tax effects 31 % 31 % State income taxes 8.84 % 8.84 % Nondeductible/nontaxable items (29 )% (38.16 )% Change in valuation allowance (10.84 )% (1.68 )% Effective income tax rate - % - %

Loss Per Share

Loss Per Share	12 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
LOSS PER SHARE	10. LOSS PER SHARE Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the year. For the Year Ended September 30, 2017 For the Year Ended September 30, 2016 Numerator: Net loss $ (4,071,983 ) (11,007,799 ) Denominator: Weighted-average shares outstanding: Weighted-average shares outstanding - Basic 212,648,770 193,981,153 Stock options - - Weighted-average shares outstanding - Diluted 212,648,770 193,981,153 Loss per share -Basic (0.02 ) (0.06 ) -Diluted (0.02 ) (0.06 ) Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES Operating Commitment The total future minimum lease payments under the non-cancellable operating lease with respect to the office as of September 30, 2017 are payable as follows: As of September 30, Amount 2018 $ 7,130 2019 - Total minimum payments $ 7,130 Rental expense was $61,093 and 29,129 for the year ended September 30, 2017 and 2016, respectively.

Subsequent Event

Subsequent Event	12 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENT	12. SUBSEQUENT EVENT The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of September 30, 2017 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the “U.S. GAAP”). All significant intercompany transactions and account balances have been eliminated. This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.
Reclassifications	Reclassifications Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.
Forward Stock split	Forward Stock split On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.
Fair Value Measurements	Fair Value Measurements The Company applies the provisions of ASC Subtopic 820-10, ”Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. - Level 3 inputs to the valuation methodology are unobservable and significant to the fair value. There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of September 30, 2017 and 2016.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2017 and 2016, the Company’s cash and cash equivalents amounted $204,851 and $173,537, respectively. All of the Company’s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.
Concentration of Credit Risk	Concentration of Credit Risk The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes. Concentration of credit risk with respect to trade and notes receivables is limited due to the wide variety of customers and markets in which the Company transacts business, as well as their dispersion across many geographical areas. The Company performs ongoing credit evaluations of its customers and generally does not require collateral, but does require advance deposits on certain transactions.
Receivable from Collaboration Partners	Receivable from Collaboration Partners Receivable from collaboration partners is stated at carrying value less estimates made for doubtful receivables. An allowance for impairment of receivable from collaboration partners is established if the collection of a receivable becomes doubtful. Such receivable becomes doubtful when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the receivable is impaired. The amount of the allowance is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. An impairment loss is recognized in the statement of operations, as are subsequent recoveries of previous impairments.
Research and Development Expenses	Research and Development Expenses The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.
Stock-based Compensation	Stock-based Compensation The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 “Compensation-Stock Compensation”. Total employee stock-based compensation expenses were $0 and $397,960 for the years ended September 30, 2017 and 2016, respectively. The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 505-50 “Equity-Based Payments to Non-Employees” which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $138,038 and $0 for the years ended September 30, 2017 and 2016, respectively.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain. Under ASC 740, a tax position is recognized as a benefit only if it is ”more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the years ended September 30, 2017 and September, 30, 2016. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition. For the years ended September 30, 2017 and 2016, the Company’s income tax expense amounted $830 and $836, respectively.
Loss Per Share of Common Stock	Loss Per Share of Common Stock The Company reports loss per share in accordance with ASC Topic 260-10 “Earnings per Share.” Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available.
Commitments and Contingencies	Commitments and Contingencies The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Revenue Recognition: Revenue from Contracts with Customers: Topic Disclosure of Going Concern Uncertainties: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Leases Stock-based Compensation Financial Instruments - Credit Losses: Statement of Cash Flows: In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): “Restricted Cash”(“ASU 2016-18”). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016-18 will become effective for us beginning April 1, 2018, or fiscal 2019. ASU 2016-18 is required to be applied retrospectively. Upon the adoption, amounts described as restricted cash will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts shown on the statements of cash flows. Business Combination From time to time, new accounting pronouncements are issued by FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption. Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying financial statements

Corrections to Previously Iss20

Corrections to Previously Issued Consolidated Financial Statements (Tables)	12 Months Ended
	Sep. 30, 2017
Accounting Changes and Error Corrections [Abstract]
Schedule of corrections and consolidated financial statements	ITEMS Previously Reported on Form 10K Adjustments No.1 Adjustments No.2 Restated Consolidated Balance Sheets As of September 30, 2016 Due to related party - 6,500,000 - 6,500,000 Total Liabilities 56,470 6,500,000 - 6,556,470 Additional paid-in capital 4,733,401 - 60 4,733,461 Accumulated deficit (4,823,401 ) (6,500,000 ) - (11,323,401 ) Total equity (deficit) 120,882 (6,500,000 ) - (6,379,118 ) Consolidated Statements of Operations and Comprehensive Loss For the year ended September 30, 2016 Selling, general and administrative expenses 4,497,263 (3,500,060 ) 60 997,263 Research and development expenses - 10,000,000 - 10,000,000 Net loss from operations (4,497,295 ) (6,499,940 ) (60 ) (10,997,295 ) Loss from continuing operations before income taxes (4,506,963 ) (6,499,940 ) (60 ) (11,006,963 ) Net Loss (4,507,799 ) (6,499,940 ) (60 ) (11,007,799 ) Basic and diluted loss per share (0.00 ) (0.06 ) (0.00 ) (0.06 ) Consolidated Statements of Cash Flow For the year ended September 30, 2016 Net loss from continuing operations (4,507,799 ) (6,499,940 ) (60 ) (11,007,799 ) Issuance of common stock for compensation 1,295,324 (60 ) 60 1,295,324 (Decrease) increase in due to related party (22,517 ) 6,500,000 6,477,483

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Sep. 30, 2017
Payables and Accruals [Abstract]
Schedule of accrued expenses	September 30, September 30, Accrued consulting fee $ 2,609 $ 23,100 Accrued audit fee - 15,000 Accrued interest expense – related party(Note 7) 8,460 - Accrued payroll 23,845 - Total $ 34,914 $ 38,100

Related Parties Transactions (T

Related Parties Transactions (Tables)	12 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Schedule of related party transactions	Name of entity or Individual Relationship with the Company and its subsidiaries BioLite Inc. (the “BioLite”) Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene BioFirst Corporation (the “BioFirst”) Entity controlled by controlling beneficiary shareholder of Yuangene Rgene Corporation (the “Rgene”) Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene Liongene Corporation (the “Liongene”) Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene Yuangene Corporation (the “Yuangene”) Controlling beneficiary shareholder of the Company Asiangene Corporation (the “Asiangene”) Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”) Shareholder of the Company Kimho Consultants Co., Ltd. (the “Kimho”) Shareholder of the Company
Schedule of amount due to related party	September 30, September 30, 2017 2016 BioLite, Inc. $ - $ 6,500,000 BioFirst Corporation 3,950,000 - Asiangene Corporation 160,000 - Yuangene Corporation 3,000 - Total $ 4,113,000 $ 6,500,000

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Summary of income tax (benefits)	For the year ended September 30, 2017 For the year ended September 30, 2016 Federal State Total Federal State Total Current $ - $ 830 $ 830 $ - $ 836 $ 836 Deferred - - - - - - $ - $ 830 $ 830 $ - $ 836 $ 836
Schedule of deferred tax	Deferred Tax Account - noncurrent: September 30, 2017 September 30, 2016 Tax losses carryforwards $ 832,913 $ 464,038 Less: Valuation allowance (832,913 ) (464,038 ) Total deferred tax account - noncurrent $ - $ -
Schedule of statutory rate and effective rate reconciliation	For the Year ended 2017 2016 Statutory federal tax benefit, net of state tax effects 31 % 31 % State income taxes 8.84 % 8.84 % Nondeductible/nontaxable items (29 )% (38.16 )% Change in valuation allowance (10.84 )% (1.68 )% Effective income tax rate - % - %

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Schedule of loss per share	For the Year Ended September 30, 2017 For the Year Ended September 30, 2016 Numerator: Net loss $ (4,071,983 ) (11,007,799 ) Denominator: Weighted-average shares outstanding: Weighted-average shares outstanding - Basic 212,648,770 193,981,153 Stock options - - Weighted-average shares outstanding - Diluted 212,648,770 193,981,153 Loss per share -Basic (0.02 ) (0.06 ) -Diluted (0.02 ) (0.06 )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments	As of September 30, Amount 2018 $ 7,130 2019 - Total minimum payments $ 7,130

Organization and Description 26

Organization and Description of Business (Details)	Feb. 08, 2016shares
Share Exchange Agreement Four [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split	205,519,223
Common stock issued pre-stock split	65,431,144
Percentage of common shares issued and outstanding	79.70%
Share Exchange Agreement [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split	164,387,376
Common stock issued pre-stock split	52,336,000
Share Exchange Agreement One [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split	166,273,921
Common stock issued pre-stock split	52,936,583
Share Exchange Agreement Three [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split	166,273,921
Common stock issued pre-stock split	52,936,583
Common stock converted to exchange ratio	0.2536
Share Exchange Agreement Two [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split	163,159,952
Common stock issued pre-stock split	51,945,225
Percentage of common shares issued and outstanding	79.70%
Percentage of issued share capital	100.00%

Corrections to Previously Iss27

Corrections to Previously Issued Consolidated Financial Statements (Details) - USD ($)	2 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2017	Sep. 30, 2016	Jul. 20, 2015
Consolidated Balance Sheets
Due to related party		$ 4,113,000	$ 6,500,000
Total Liabilities		4,147,914	6,556,470
Additional paid-in capital		13,788,574	4,733,461
Accumulated deficit		(15,395,384)	(11,323,401)
Total equity (deficit)	$ 633,357	(1,393,063)	(6,379,118)	$ 897,001
Consolidated Statements of Operations and Comprehensive Loss
Selling, general and administrative expenses		707,142	599,303
Research and development expenses		3,151,162	10,000,000
Net loss from operations		(3,996,342)	(10,997,295)
Loss from continuing operations before income taxes		(4,071,153)	(11,006,963)
Net Loss	(315,602)	$ (4,071,983)	$ (11,007,799)
Basic and diluted loss per share		$ (0.02)	$ (0.06)
Consolidated Statements of Cash Flow
Net loss from continuing operations	$ (315,602)	$ (4,071,983)	$ (11,007,799)
Issuance of common stock for compensation			1,295,324
(Decrease) increase in due to related party		$ 2,353,000	6,477,483
Scenario, Previously Reported [Member]
Consolidated Balance Sheets
Due to related party
Total Liabilities			56,470
Additional paid-in capital			4,733,401
Accumulated deficit			(4,823,401)
Total equity (deficit)			120,882
Consolidated Statements of Operations and Comprehensive Loss
Selling, general and administrative expenses			4,497,263
Research and development expenses
Net loss from operations			(4,497,295)
Loss from continuing operations before income taxes			(4,506,963)
Net Loss			$ (4,507,799)
Basic and diluted loss per share			$ 0
Consolidated Statements of Cash Flow
Net loss from continuing operations			$ (4,507,799)
Issuance of common stock for compensation			1,295,324
(Decrease) increase in due to related party			(22,517)
Restatement Adjustment [Member]
Consolidated Balance Sheets
Due to related party			6,500,000
Total Liabilities			6,556,470
Additional paid-in capital			4,733,461
Accumulated deficit			(11,323,401)
Total equity (deficit)			(6,379,118)
Consolidated Statements of Operations and Comprehensive Loss
Selling, general and administrative expenses			997,263
Research and development expenses			10,000,000
Net loss from operations			(10,997,295)
Loss from continuing operations before income taxes			(11,006,963)
Net Loss			$ (11,007,799)
Basic and diluted loss per share			$ (0.06)
Consolidated Statements of Cash Flow
Net loss from continuing operations			$ (11,007,799)
Issuance of common stock for compensation			1,295,324
(Decrease) increase in due to related party			6,477,483
Adjustments One [Member]
Consolidated Balance Sheets
Due to related party
Total Liabilities
Additional paid-in capital			60
Accumulated deficit
Total equity (deficit)
Consolidated Statements of Operations and Comprehensive Loss
Selling, general and administrative expenses			60
Research and development expenses
Net loss from operations			(60)
Loss from continuing operations before income taxes			(60)
Net Loss			$ (60)
Basic and diluted loss per share			$ 0
Consolidated Statements of Cash Flow
Net loss from continuing operations			$ (60)
Issuance of common stock for compensation			60
(Decrease) increase in due to related party
Adjustments [Member]
Consolidated Balance Sheets
Due to related party			6,500,000
Total Liabilities			6,500,000
Additional paid-in capital
Accumulated deficit			(6,500,000)
Total equity (deficit)			(6,500,000)
Consolidated Statements of Operations and Comprehensive Loss
Selling, general and administrative expenses			(3,500,060)
Research and development expenses			10,000,000
Net loss from operations			(6,499,940)
Loss from continuing operations before income taxes			(6,499,940)
Net Loss			$ (6,499,940)
Basic and diluted loss per share			$ (0.06)
Consolidated Statements of Cash Flow
Net loss from continuing operations			$ (6,499,940)
Issuance of common stock for compensation			(60)
(Decrease) increase in due to related party			$ 6,500,000

Corrections to Previously Iss28

Corrections to Previously Issued Consolidated Financial Statements (Details Textual) - USD ($)	2 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2017	Sep. 30, 2016	Jul. 20, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Due to related party		$ 4,113,000	$ 6,500,000
Total liabilities		4,147,914	6,556,470
Total liabilities increased		6,500,000
Additional paid in capital		13,788,574	4,733,461
Additional paid in capital increased		60
Accumulated deficit		(15,395,384)	(11,323,401)
Accumulated deficit increased		6,500,000
Total equity (deficit)	$ 633,357	(1,393,063)	(6,379,118)	$ 897,001
Total equity (deficit) decreased		6,500,000
Selling, general and administrative expenses		707,142	599,303
Selling, general and administrative expenses decreased		3,500,000
Research and development expenses		3,151,162	10,000,000
Research and development expenses increased		10,000,000
Net loss from operations		(3,996,342)	(10,997,295)
Loss from continuing operations before taxes		(4,071,153)	(11,006,963)
Loss from continuing operations before taxes increased		6,500,000
Net loss for the period	(315,602)	$ (4,071,983)	$ (11,007,799)
Basic and diluted loss per share		$ (0.02)	$ (0.06)
Basic and diluted loss per share increased		$ 0.06
Net loss from continuing operations	$ (315,602)	$ (4,071,983)	$ (11,007,799)
Net loss from continuing operations increased		6,500,000
Issuance of common stock for compensation and recapitalization			1,295,324
(Decrease) increase in due to related party		2,353,000	6,477,483
(Decrease) increase in due to related party increased		$ 6,500,000
Scenario, Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Due to related party
Total liabilities			56,470
Additional paid in capital			4,733,401
Accumulated deficit			(4,823,401)
Total equity (deficit)			120,882
Selling, general and administrative expenses			4,497,263
Research and development expenses
Net loss from operations			(4,497,295)
Loss from continuing operations before taxes			(4,506,963)
Net loss for the period			$ (4,507,799)
Basic and diluted loss per share			$ 0
Net loss from continuing operations			$ (4,507,799)
Issuance of common stock for compensation and recapitalization			1,295,324
(Decrease) increase in due to related party			(22,517)
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Due to related party			6,500,000
Total liabilities			6,556,470
Additional paid in capital			4,733,461
Accumulated deficit			(11,323,401)
Total equity (deficit)			(6,379,118)
Selling, general and administrative expenses			997,263
Research and development expenses			10,000,000
Net loss from operations			(10,997,295)
Loss from continuing operations before taxes			(11,006,963)
Net loss for the period			$ (11,007,799)
Basic and diluted loss per share			$ (0.06)
Net loss from continuing operations			$ (11,007,799)
Issuance of common stock for compensation and recapitalization			1,295,324
(Decrease) increase in due to related party			6,477,483
Adjustments One [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Due to related party
Total liabilities
Additional paid in capital			60
Accumulated deficit
Total equity (deficit)
Selling, general and administrative expenses			60
Research and development expenses
Net loss from operations			(60)
Loss from continuing operations before taxes			(60)
Net loss for the period			$ (60)
Basic and diluted loss per share			$ 0
Net loss from continuing operations			$ (60)
Issuance of common stock for compensation and recapitalization			60
(Decrease) increase in due to related party
Adjustments [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Due to related party			6,500,000
Total liabilities			6,500,000
Additional paid in capital
Accumulated deficit			(6,500,000)
Total equity (deficit)			(6,500,000)
Selling, general and administrative expenses			(3,500,060)
Research and development expenses			10,000,000
Net loss from operations			(6,499,940)
Loss from continuing operations before taxes			(6,499,940)
Net loss for the period			$ (6,499,940)
Basic and diluted loss per share			$ (0.06)
Net loss from continuing operations			$ (6,499,940)
Issuance of common stock for compensation and recapitalization			(60)
(Decrease) increase in due to related party			$ 6,500,000

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details) - USD ($)	Mar. 21, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015	Jul. 21, 2015
Summary of Significant Accounting Policies (Textual)
Forward split ratio	1 to 3:141
Common stock, par value		$ 0.001	$ 0.001
Common stock, authorized		360,000,000	360,000,000
Cash and cash equivalents amounted		$ 204,851	$ 173,537	$ 994,830
Income tax expense		830	836
Stock-based compensation expenses		138,038	397,960
Non-employee stock-based compensation expenses		$ 138,038

Going Concern (Details)

Going Concern (Details) - USD ($)	May 06, 2016	Jul. 24, 2017	May 26, 2017	Feb. 28, 2017	Mar. 31, 2016	Sep. 30, 2015	Sep. 30, 2017	Sep. 30, 2016
Going Concern (Textual)
Accumulated deficit							$ (15,395,384)	$ (11,323,401)
Net loss for the period						$ (315,602)	(4,071,983)	(11,007,799)
Common stock newly issued, value						$ 51,958	5,850,000	3,250,000
Working capital deficiency							$ 1,393,063	$ 6,382,933
Collaborative Arrangement [Member]
Going Concern (Textual)
Milestone payments to BioLite in cash	$ 2,600,000
Common stock newly issued, value	$ 900,000	$ 3,000,000
Issuance of common shares, shares	562,500
Share price	$ 1.60			$ 2
Percentage of payments under collaborative agreement		50.00%		15.00%			3.50%
Accounts payable				$ 15,000,000
Co-Dev Agreement [Member]
Going Concern (Textual)
Common stock newly issued, value							$ 3,000,000
Percentage of payments under collaborative agreement			50.00%
Collaborative Arrangement One [Member]
Going Concern (Textual)
Milestone payments to BioLite in cash				650,000
Common stock newly issued, value				$ 5,850,000
Issuance of common shares, shares				2,925,000
Share price				$ 2
Percentage of payments under collaborative agreement					6.50%
Accounts payable					$ 6,500,000

Collaborative Agreements (Detai

Collaborative Agreements (Details) - USD ($)	May 06, 2016	Jul. 24, 2017	May 26, 2017	Feb. 28, 2017	Mar. 31, 2016	Sep. 30, 2015	Sep. 30, 2017	Sep. 30, 2016	Jun. 01, 2017	Aug. 26, 2016	Dec. 29, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amount received from BriVision							$ 4,113,000	$ 6,500,000
Common stock newly issued, value						$ 51,958	5,850,000	3,250,000
Research and development expense							$ 3,151,162	$ 10,000,000
Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Description of payment settlement schedule							● upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week. ● upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week. ● at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months. ● upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week. ● at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months. ● upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.
Amount received from BriVision		$ 3,000,000									$ 100,000,000
Upfront payments							$ 3,500,000
Percentage of payments under collaborative agreement		50.00%		15.00%			3.50%
Milestone payments to BioLite in cash	$ 2,600,000
Common stock newly issued, value	$ 900,000	$ 3,000,000
Common stock newly issued, shares	562,500
Share price	$ 1.60			$ 2
Licensing rights							$ 10,000,000
Accounts payable				$ 15,000,000
Co-Dev Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amount received from BriVision			$ 3,000,000						$ 450,000
Percentage of payments under collaborative agreement			50.00%
Common stock newly issued, value							3,000,000
Company cash payments			$ 3,000,000
Collaborative Arrangement One [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amount received from BriVision										$ 100,000,000
Percentage of payments under collaborative agreement					6.50%
Milestone payments to BioLite in cash				650,000
Common stock newly issued, value				$ 5,850,000
Common stock newly issued, shares				2,925,000
Share price				$ 2
Licensing rights							3,000,000
Accounts payable					$ 6,500,000
Research and development expense							$ 3,000,000

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Sep. 30, 2017	Sep. 30, 2016
Payables and Accruals [Abstract]
Accrued consulting fee	$ 2,609	$ 23,100
Accrued audit fee		15,000
Accrued interest expense – related party(Note 7)	8,460
Accrued payroll	23,845
Total	$ 34,914	$ 38,100

Related Parties Transactions (D

Related Parties Transactions (Details)	12 Months Ended
	Sep. 30, 2017
BioFirst Corporation [Member]
Relationship with the Company and its subsidiaries, description	Entity controlled by controlling beneficiary shareholder of Yuangene
Rgene Corporation [Member]
Relationship with the Company and its subsidiaries, description	Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Liongene Corporation [Member]
Relationship with the Company and its subsidiaries, description	Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Yuangene Corporation [Member]
Relationship with the Company and its subsidiaries, description	Controlling beneficiary shareholder of the Company
Asiangene Corporation [Member]
Relationship with the Company and its subsidiaries, description	Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene
Euro-Asia [Member]
Relationship with the Company and its subsidiaries, description	Shareholder of the Company
Kimho Consultants [Member]
Relationship with the Company and its subsidiaries, description	Shareholder of the Company
BioLite Inc [Member]
Relationship with the Company and its subsidiaries, description	Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene

Related Parties Transactions 34

Related Parties Transactions (Details 1) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Dec. 29, 2015
Due to related parties	$ 4,113,000	$ 6,500,000
Asiangene Corporation [Member]
Due to related parties	160,000
BioLite Collaborative Agreement [Member]
Due to related parties	0	6,500,000	$ 100,000,000
Yuangene Corporation [Member]
Due to related parties	3,000
BioLite Inc [Member]
Due to related parties		6,500,000
BioFirst Corporation [Member]
Due to related parties	3,950,000
Co-Dev Agreement [Member]
Due to related parties	$ 450,000

Related Parties Transactions 35

Related Parties Transactions (Details Textual) - USD ($)	1 Months Ended		2 Months Ended	12 Months Ended
	May 26, 2017	Jan. 26, 2017	Sep. 30, 2015	Sep. 30, 2017	Sep. 30, 2016	Dec. 29, 2015
Related Parties Transactions (Textual)
Amount received from BriVision				$ 4,113,000	$ 6,500,000
Outstanding loan				950,000
Accrued interest				8,460
Interest expenses				74,960	10,170
Common stock new issues			$ 51,958	5,850,000	3,250,000
Stock based compensation expenses				138,038	397,960
Consulting service				70,000
Additional paid-in capital				13,788,574	4,733,461
Lease rent				5,000
Rent expenses				$ 52,205	0
Related party transactions, description				Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by Asiangene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. Asiangene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. As of September 30, 2017, the outstanding loan balance is $160,000.
Co-Dev Agreement [Member]
Related Parties Transactions (Textual)
Amount received from BriVision				$ 450,000
Common stock new issues	$ 2,550,000			3,000,000
Loan Agreement [Member]
Related Parties Transactions (Textual)
Total commitment		$ 950,000
Loan agreement, description		The loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender.
KimhoAgreementtMember
Related Parties Transactions (Textual)
Stock based compensation expenses				80,000
EuroAsiaAgreementMember
Related Parties Transactions (Textual)
Stock based compensation expenses				55,000
Yuangene Corporation [Member]
Related Parties Transactions (Textual)
Amount received from BriVision				3,000
Aggregate working capital				$ 3,000
Interest rate percentage				0.00%
Outstanding advance				$ 3,000
Additional paid-in capital				70,000
BioLite Collaborative Agreement [Member]
Related Parties Transactions (Textual)
Amount received from BriVision				0	6,500,000	$ 100,000,000
BioLite Inc [Member]
Related Parties Transactions (Textual)
Amount received from BriVision					6,500,000
BioFirst Corporation [Member]
Related Parties Transactions (Textual)
Amount received from BriVision				3,950,000
Asiangene Corporation [Member]
Related Parties Transactions (Textual)
Amount received from BriVision				160,000
BioFirst Collaborative Agreement Agreement [Member]
Related Parties Transactions (Textual)
Due to BioFirst				$ 3,000,000

Equity (Details)

Equity (Details) - USD ($)

May 06, 2016

Mar. 21, 2016

Feb. 08, 2016

Jul. 24, 2017

May 26, 2017

Feb. 28, 2017

Oct. 02, 2016

Aug. 26, 2016

Mar. 31, 2016

Feb. 17, 2016

Sep. 30, 2015

Sep. 30, 2017

Sep. 30, 2016

Jun. 01, 2017

Dec. 29, 2015

Oct. 30, 2015

Equity (Textual)

Common stock, authorized

360,000,000

360,000,000

Common stock, par value

$ 0.001

$ 0.001

Description of forward split

1 to 3:141

Subscription receivable

$ 350,000

$ 350,000

Issuance of common shares

$ 51,958

5,850,000

3,250,000

Due to related parties

4,113,000

6,500,000

Stock based compensation expenses

138,038

$ 397,960

Non-employee stock-based compensation

$ 3,038

Collaborative Arrangement [Member]

Equity (Textual)

Issuance of common shares

$ 900,000

$ 3,000,000

Issuance of common shares, shares

562,500

Share price

$ 1.60

$ 2

Due to related parties

$ 3,000,000

$ 100,000,000

Total payment upon first IND submission

$ 15,000,000

Percentage of payments under collaborative agreement

50.00%

15.00%

3.50%

Consulting agreement, description

Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s common stock at $1.00 per share for any amount exceeding $3,000.

Share Exchange Agreement [Member]

Equity (Textual)

Common stock issued pre-stock split

52,336,000

Common stock issued post-stock split

164,387,376

Share Exchange Agreement Two [Member]

Equity (Textual)

Common stock issued pre-stock split

51,945,225

Common stock issued post-stock split

163,159,952

Percentage of common shares issued and outstanding

79.70%

Percentage of issued share capital

100.00%

Share Exchange Agreement Three [Member]

Equity (Textual)

Common stock issued pre-stock split

52,936,583

Common stock issued post-stock split

166,273,921

Exchange ratio

0.2536-for-1

Share Exchange Agreement One [Member]

Equity (Textual)

Common stock issued pre-stock split

52,936,583

Common stock issued post-stock split

166,273,921

Share Exchange Agreement Four [Member]

Equity (Textual)

Common stock issued pre-stock split

65,431,144

Common stock issued post-stock split

205,519,223

Percentage of common shares issued and outstanding

79.70%

Co-Dev Agreement [Member]

Equity (Textual)

Issuance of common shares

$ 3,000,000

Company cash payments

$ 3,000,000

Due to related parties

$ 3,000,000

$ 450,000

Percentage of payments under collaborative agreement

50.00%

Collaborative Arrangement One [Member]

Equity (Textual)

Issuance of common shares

$ 5,850,000

Issuance of common shares, shares

2,925,000

Share price

$ 2

Due to related parties

$ 100,000,000

Total payment upon first IND submission

$ 6,500,000

Percentage of payments under collaborative agreement

6.50%

Remitted amount

$ 650,000

Kimho Agreement [Member]

Equity (Textual)

Professional fees

113,000

Stock based compensation expenses

80,000

Euro-Asia Agreement [Member]

Equity (Textual)

Professional fees

69,000

Stock based compensation expenses

$ 55,000

Equity Incentive Plan [Member]

Equity (Textual)

Common stock issued pre-stock split

50,000

Common stock issued post-stock split

157,050

BioLite Inc [Member]

Equity (Textual)

Common stock, par value

$ 0.001

Issuance of common shares

$ 1,468,750

Purchase price per share

$ 1.60

Net proceeds from offering

$ 2,350,000

Income Tax (Details)

Income Tax (Details) - USD ($)	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Federal
Current
Deferred
Federal Total
State
Current	830	836
Deferred
State total	830	836
Current total	830	836
Deferred total
Total	$ 830	$ 836

Income Tax (Details 1)

Income Tax (Details 1) - USD ($)	Sep. 30, 2017	Sep. 30, 2016
Deferred Tax Account - noncurrent:
Tax losses carryforwards	$ 832,913	$ 464,038
Less: Valuation allowance	(832,913)	(464,038)
Total deferred tax account - noncurrent

Income Tax (Details 2)

Income Tax (Details 2)	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Statutory federal tax benefit, net of state tax effects	31.00%	31.00%
State income taxes	8.84%	8.84%
Nondeductible/nontaxable items	(29.00%)	(38.16%)
Change in valuation allowance	(10.84%)	(1.68%)
Effective income tax rate

Loss Per Share (Details)

Loss Per Share (Details) - USD ($)	2 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2017	Sep. 30, 2016
Numerator:
Net loss for the period	$ (315,602)	$ (4,071,983)	$ (11,007,799)
Weighted-average shares outstanding:
Weighted-average shares outstanding - Basic		212,648,770	193,981,153
Stock options
Weighted-average shares outstanding - Diluted		212,648,770	193,981,153
Loss per share
-Basic		$ (0.02)	$ (0.06)
-Diluted		$ (0.02)	$ (0.06)

Commitments and Contingencies41

Commitments and Contingencies (Details)	Sep. 30, 2017USD ($)
Operating Leases, Future Minimum Payments [Abstract]
2,018	$ 7,130
2,019
Total minimum payments	$ 7,130

Commitments and Contingencies42

Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Commitments and Contingencies (Textual)
Rent expense	$ 61,093	$ 29,129